{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:21:16Z","timestamp":1787437276315,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,22]]},"DOI":"10.7759\/cureus.114990","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T21:24:20Z","timestamp":1787433860000},"source":"Crossref","is-referenced-by-count":0,"title":["Multiorgan Toxicity Following Rifapentine and Isoniazid Therapy for Latent Tuberculosis Infection: A Case Report"],"prefix":"10.7759","author":[{"given":"Shayan","family":"Parvini Najafabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Fiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben RM","year":"2016","unstructured":"Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016, 13:e1002152. 10.1371\/journal.pmed.1002152","journal-title":"PLoS Med"},{"key":"ref2","article-title":"Latent tuberculosis","author":"Price C","year":"2024","unstructured":"Price C, Nguyen A. Latent tuberculosis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent tuberculosis infection","volume":"385","author":"Shah M","year":"2021","unstructured":"Shah M, Dorman SE. Latent tuberculosis infection. N Engl J Med. 2021, 385:2271-80. 10.1056\/NEJMcp2108501","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov AS","year":"2018","unstructured":"Borisov AS, Bamrah Morris S, Njie GJ, et al.. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018, 67:723-6. 10.15585\/mmwr.mm6725a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad083","article-title":"Symptoms and systemic drug reactions in persons receiving weekly rifapentine plus isoniazid (3HP) treatment for latent tuberculosis infection","volume":"76","author":"Sadowski C","year":"2023","unstructured":"Sadowski C, Belknap R, Holland DP, et al.. Symptoms and systemic drug reactions in persons receiving weekly rifapentine plus isoniazid (3HP) treatment for latent tuberculosis infection. Clin Infect Dis. 2023, 76:2090-7. 10.1093\/cid\/ciad083","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199911000-00001","article-title":"Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions","volume":"78","author":"Mart\u00ednez E","year":"1999","unstructured":"Mart\u00ednez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999, 78:361-9. 10.1097\/00005792-199911000-00001","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling TR","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al.. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011, 365:2155-66. 10.1056\/NEJMoa1104875","journal-title":"N Engl J Med"},{"key":"ref8","article-title":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury","year":"2019","unstructured":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. LiverTox. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2019."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle JH","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019, 381:264-73. 10.1056\/NEJMra1816149","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6520-20","article-title":"Isoniazid-induced immune thrombocytopenia","volume":"60","author":"Kuwabara G","year":"2021","unstructured":"Kuwabara G, Tazoe K, Imoto W, et al.. Isoniazid-induced immune thrombocytopenia. Intern Med. 2021, 60:3639-43. 10.2169\/internalmedicine.6520-20","journal-title":"Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.11.021","article-title":"Antituberculosis drug-associated DRESS: a case series","volume":"6","author":"Allouchery M","year":"2018","unstructured":"Allouchery M, Logerot S, Cottin J, Pralong P, Villier C, Ben Sa\u00efd B. Antituberculosis drug-associated DRESS: a case series. J Allergy Clin Immunol Pract. 2018, 6:1373-80. 10.1016\/j.jaip.2017.11.021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(86)90202-X","article-title":"Safety of pyridoxine - a review of human and animal studies","volume":"34","author":"Cohen M","year":"1986","unstructured":"Cohen M, Bendich A. Safety of pyridoxine - a review of human and animal studies. Toxicol Lett. 1986, 34:129-39. 10.1016\/0378-4274(86)90202-X","journal-title":"Toxicol Lett"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore EE","year":"2015","unstructured":"Bliven-Sizemore EE, Sterling TR, Shang N, et al.. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015, 19:1039-44. 10.5588\/ijtld.14.0829","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter JI","year":"2025","unstructured":"Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025, 392:584-98. 10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw218","article-title":"From the cover: characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury","volume":"155","author":"Usui T","year":"2017","unstructured":"Usui T, Meng X, Saide K, et al.. From the cover: characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury. Toxicol Sci. 2017, 155:420-31. 10.1093\/toxsci\/kfw218","journal-title":"Toxicol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9428460","article-title":"Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features","volume":"31","author":"De Vriese AS","year":"1998","unstructured":"De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998, 31:108-15. 10.1053\/ajkd.1998.v31.pm9428460","journal-title":"Am J Kidney Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana RJ","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023, 77:1036-65. 10.1002\/hep.32689","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster RH","year":"2007","unstructured":"Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007, 357:580-7. 10.1056\/NEJMra066469","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.4.924","article-title":"Rifampicin-induced acute renal failure: a series of 60 patients","volume":"13","author":"Covic A","year":"1998","unstructured":"Covic A, Goldsmith DJ, Segall L, Stoicescu C, Lungu S, Volovat C, Covic M. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant. 1998, 13:924-9. 10.1093\/ndt\/13.4.924","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510358-multiorgan-toxicity-following-rifapentine-and-isoniazid-therapy-for-latent-tuberculosis-infection-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T21:24:22Z","timestamp":1787433862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510358-multiorgan-toxicity-following-rifapentine-and-isoniazid-therapy-for-latent-tuberculosis-infection-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.114990","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}